Sign In
Buy HAE
$65.88
-0.490 (-0.738%)
At Close: Jun 03, 2026
Haemonetics (HAE) Reports Q1 Earnings: What Key Metrics Have to Say
10:36am, Thursday, 07'th Aug 2025
While the top- and bottom-line numbers for Haemonetics (HAE) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare
Haemonetics (HAE) Q1 Earnings and Revenues Surpass Estimates
08:11am, Thursday, 07'th Aug 2025
Haemonetics (HAE) came out with quarterly earnings of $1.1 per share, beating the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $1.02 per share a year ago.
Haemonetics 1st Quarter Fiscal Year 2026 Earnings Release Available on Investor Relations Website
06:00am, Thursday, 07'th Aug 2025
Financial release accessible online BOSTON , Aug. 7, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its first quarter fiscal year 2026, which ended June
Unlocking Q1 Potential of Haemonetics (HAE): Exploring Wall Street Estimates for Key Metrics
10:16am, Wednesday, 06'th Aug 2025
Beyond analysts' top-and-bottom-line estimates for Haemonetics (HAE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quart
Analysts Estimate Haemonetics (HAE) to Report a Decline in Earnings: What to Look Out for
11:08am, Thursday, 31'st Jul 2025
Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pharvaris: Deucrictibant Advanced To Target Two Sets Of HAE Patient Populations
03:15pm, Wednesday, 23'rd Jul 2025
Pharvaris is advancing deucrictibant, an oral bradykinin B2-receptor antagonist, in two late-stage trials for hereditary angioedema patient populations. Key catalysts include RAPIDe-3 phase 3 topline
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that positive results from the Phase 3 OASISplus prospective switch study of donidalorsen in patients with
Pharvaris: More Convenience, More Potency, And More Potential For Future HAE Success
04:41am, Friday, 18'th Jul 2025
Pharvaris is a late-stage biopharma that specializes in the treatment of hereditary angioedema (HAE). They have only one drug in their pipeline, deucrictibant, of which they are making two oral formul
Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2026 Results: August 7, 2025
04:05pm, Wednesday, 09'th Jul 2025
BOSTON , July 9, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish first quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, Aug
KalVista: FDA Approval Of EKTERLY As Oral On-Demand HAE Drug Is Just Beginning
03:52pm, Tuesday, 08'th Jul 2025
FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy, providing a major competitive advantage over injectable options. EKTERLY's convenience an
Live Nasdaq Composite: Markets Rev Engines for Potential All-Time Highs
02:09pm, Friday, 27'th Jun 2025
Live Updates Live Coverage Has Ended So Close and Yet so Far 4:09 pm by Gerelyn Terzo The S&P 500 and Nasdaq Composite indices both crossed over into record territory during today’s trading
ZUG, Switzerland, June 27, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet nee
KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada
07:00am, Thursday, 26'th Jun 2025
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, Ltd., has granted Pend
ANDEMBRY inhibits the top of the HAE cascade by targeting factor XIIa and provides sustained protection from attacks Once-monthly dosing reduced HAE attacks by a median of more than 99 percent and a l
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the presentation of new data at the European Academy of Allergy and Clinical Immun
